Pharmaceuticals Industry Trends India - 2022

Market Monitor

  • India
  • Chemie/Farmacie

15 mrt 2022

Increase in production of primary products planned to lower reliance on China

IT India pharma credit risk 2022

Indian pharmaceuticals value added output is forecast to grow more than 6% annually in 2022 and in 2023, due to the ongoing rollout of Covid-19 vaccinations, a rebound in non-Covid related medical treatments and a surge in generic drug exports. However, in H1 of 2022 drug producers still face pressure on gross margins, due to high commodity and transport costs. Domestic wholesalers and pharmacies continue to generate low, but stable margins.

IT India pharma output 2022

While generic drugs still account for about 70% of output, the pandemic has spurred Indian drug producers to substantially increase their R&D spending. Due to a serious supply disruption in 2020, Indian drug producers intend to increase local production of Active Pharmaceutical Ingredients (APIs) in order to reduce their reliance on Chinese deliveries. Those imports have meanwhile rebounded, but are not yet back to pre-pandemic levels. The government has announced a large incentive scheme (e.g. with tax exemptions) to boost local API production, which will last until 2030.
 
The industry is highly export-oriented, being one of the leading suppliers of generic drugs to the US. Exports could be impacted by resumption of US Food and Drug Administration (USFDA) inspections of Indian production plants. Failures to meet required quality standards could lead to lower sales to the US, and could have a negative effect on margins.

We expect the domestic drug market to grow steadily in the coming years, due to demographic trends and rising household income. The growing middle class can increasingly afford high quality drugs, while demand for treatments (and related drugs) of cardiovascular diseases and other chronic diseases will increase.

The balance sheets of most Indian pharmaceutical businesses and their capacity to generate cash are strong. Both gearing and dependence on bank finance are low. Payment behaviour has been good over the past two years, and we expect the number of protracted payments and business failures to remain low in 2022. Given the benign credit risk situation of most businesses and good growth prospects in the coming years, our underwriting stance is open for all segments.
 

Disclaimer

Elke publicatie die beschikbaar is op of vanaf onze websites, zoals, maar niet beperkt tot webpagina's, rapporten, artikelen, publicaties, tips en nuttige content, blogs, infographics, video's (hierna ‘Publicatie’) wordt louter ter informatie verstrekt en is niet bedoeld als beleggingsadvies, juridisch advies of enige aanbeveling aan de lezer(s) met betrekking tot specifieke transacties, investeringen of strategieën. Lezers zijn zelf verantwoordelijk voor het nemen van commerciële en andere beslissingen omtrent de verstrekte informatie. Hoewel Atradius al het noodzakelijke heeft gedaan om te verzekeren dat de informatie in enige Publicatie verkregen is van betrouwbare bronnen, kan Atradius niet verantwoordelijk gesteld worden voor fouten of omissies, of voor de resultaten verkregen door gebruik van deze informatie. Alle informatie in enige Publicatie wordt gegeven ‘zoals ze is’, zonder garantie op volledigheid, accuraatheid, tijdsgebondenheid, of op de resultaten verkregen door gebruik van de publicatie, en zonder garantie van enige soort, uitdrukkelijk of geïmpliceerd. In geen geval zal Atradius, haar gerelateerde partners of corporaties, of de partners, agenten of werknemers hiervan verantwoordelijk gesteld kunnen worden voor enige genomen beslissing of actie die zij zouden nemen op basis van de in enige Publicatie verstrekte informatie, of voor enig verlies van kansen, winstderving, productieverlies, omzetverlies of gevolgschade, speciale of soortgelijke schade van welke aard dan ook, zelfs wanneer de lezer in kennis is gesteld van de mogelijkheid van dergelijke verliezen of schade.